AcelRx Pharmaceuticals to Present at Two Upcoming Conferences

Rhea-AI Summary

AcelRx Pharmaceuticals (Nasdaq: ACRX), a specialty pharmaceutical company, will present at two upcoming conferences: the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020 and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 16, 2020. The management will provide business updates and participate in one-on-one investor meetings. A live webcast can be accessed via the company’s website. Replays will be available for 90 days after the events.

REDWOOD CITY, Calif., Sept. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference taking place September 14-16, 2020, and at the Cantor Fitzgerald Virtual Global Healthcare Conference taking place September 15-17, 2020.

Details of the events are as follows:

H.C. Wainwright & Co. 22^nd Annual Global Investment Conference
Date: Monday, September 14, 2020
Presentation Time: 4:30 PM Eastern Time / 1:30 PM Pacific Time

Cantor Fitzgerald Virtual Global Healthcare Conference
Date: Wednesday, September 16, 2020
Presentation Time (Fireside Chat): 4:00 PM Eastern Time / 1:00 PM Pacific Time

A live webcast link of both of the events can be found on the Company's website at http://ir.acelrx.com/upcoming-events. Management will also be hosting one-on-one investor meetings throughout the day.

For those not available to listen to the live webcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-two-upcoming-conferences-301127962.html

SOURCE AcelRx Pharmaceuticals, Inc.

FAQ

When will AcelRx Pharmaceuticals present at the H.C. Wainwright conference?

AcelRx will present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020, at 4:30 PM Eastern Time.

What is the date for AcelRx's presentation at the Cantor Fitzgerald conference?

AcelRx will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 16, 2020, during a fireside chat at 4:00 PM Eastern Time.

Where can I access the live webcasts of AcelRx's presentations?

The live webcasts can be accessed on AcelRx Pharmaceuticals' website at http://ir.acelrx.com/upcoming-events.

How long will the replays of AcelRx's conference presentations be available?

Replays of AcelRx's conference presentations will be archived for 90 days.

What business updates will AcelRx Pharmaceuticals provide during the conferences?

AcelRx management will provide an overview of the business and company updates, including their innovative therapies for medically supervised settings.